Drug Profile
Research programme: anti-R24 monoclonal antibodies - Viragen
Alternative Names: Anti-GD3 monoclonal antibody - Viragen; Anti-R24 monoclonal antibody - Viragen; VG 101Latest Information Update: 08 May 2007
Price :
$50
*
At a glance
- Originator Memorial Sloan-Kettering Cancer Center; Viragen
- Class Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Malignant melanoma
Most Recent Events
- 08 May 2007 Discontinued - Preclinical for Malignant melanoma in USA (IV-infusion)
- 10 Nov 2004 Preclinical trials in Malignant melanoma in USA (IV-infusion)
- 27 Jul 2004 The anti-R24 monoclonal antibody is available for licensing (http://www.viragen.com)